Low-Dose Erlotinib Shows Promise in Elderly, Frail Patients with EGFR+ NSCLC

A phase II study indicated that low-dose erlotinib (Tarceva) appears to be safe and effective in elderly or frail patients with EGFR mutation-positive non-small cell lung cancer.

Source: CancerNetwork - May 22, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news